THURSDAY, Nov. 19, 2020 (HealthDay News) — Among patients with previously untreated advanced ALK-positive non-small cell lung cancer (NSCLC), progression-free survival is significantly longer for those who receive first-line therapy with lorlatinib versus crizotinib, according to a study published in the Nov. 19 issue of the New England Journal of Medicine. Alice T. Shaw, M.D.,...